Back to top
more

Inspire Medical Systems (INSP)

(Delayed Data from NYSE)

$159.60 USD

159.60
1,039,945

-8.23 (-4.90%)

Updated May 13, 2024 04:00 PM ET

After-Market: $159.72 +0.12 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down

by Zacks Equity Research

Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.

National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.

Inspire (INSP) Loses -31.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Inspire (INSP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.

Inspire (INSP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 46.03% and 1.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will These 5 Medical Device Stocks Beat This Earnings Season?

by Zacks Equity Research

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.

Gear Up for Inspire (INSP) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Inspire (INSP) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs

by Zacks Equity Research

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Inspire Medical Systems (INSP) Stock Moves -0.8%: What You Should Know

by Zacks Equity Research

Inspire Medical Systems (INSP) closed at $241.66 in the latest trading session, marking a -0.8% move from the prior day.

Here's Why You Should Buy Bruker (BRKR) Stock Right Now

by Zacks Equity Research

Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.

Riya Anand headshot

How You Should Play Hologic (HOLX) Ahead of Q2 Earnings

by Riya Anand

Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.

Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.

Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up

by Zacks Equity Research

Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.

Moumi Mondal headshot

Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?

by Moumi Mondal

Lifeward's (LFWD) first-quarter 2024 results are expected to reflect the benefits of several milestone achievements from last year.

ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.

ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.

Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up

by Zacks Equity Research

Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

by Zacks Equity Research

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View

by Zacks Equity Research

Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.

Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up

by Zacks Equity Research

Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

by Zacks Equity Research

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.